Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lipella Pharmaceuticals, Inc. ( (LIPO) ) has provided an update.
On September 18, 2025, Lipella Pharmaceuticals announced positive final results from a completed Phase 2a study of LP-10, a proprietary liposomal tacrolimus oral rinse, for treating oral lichen planus (OLP). The study, conducted at five U.S. clinical sites with 27 patients, met its primary safety endpoint and showed statistically significant improvements in efficacy measures, suggesting LP-10’s potential as the first FDA-approved therapy for OLP. The company plans to advance LP-10 into late-stage development, preparing for a Phase 2b study and exploring strategic partnerships, which could significantly impact the treatment landscape for the estimated 6 million Americans affected by this condition.
The most recent analyst rating on (LIPO) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.
More about Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on reformulating and optimizing existing active pharmaceutical ingredients for new therapeutic applications in diseases with high unmet needs. The company is known for its innovative mucosal delivery solutions and completed its initial public offering in 2022.
Average Trading Volume: 16,338
Technical Sentiment Signal: Hold
Current Market Cap: $2.77M
See more data about LIPO stock on TipRanks’ Stock Analysis page.